GlassScriptPhysician profile
Alon Y Mass
NPI 1447511191
$1,135.28
in general payments reported to CMS, 2019-2025
25 companies · $390 in 2025
The $390 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $57.94 · 2021: $169 · 2022: $157 · 2023: $182 · 2024: $62.48 · 2025: $390.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $143.67 | 2023 | Urolift |
| Axonics, INC. | $141.46 | 2022 | |
| Antares Pharma, INC. | $111.56 | 2020-2025 | Xyosted |
| Boston Scientific Corporation | $87.01 | 2019 | |
| Olympus America INC. | $76.94 | 2025 | Itind System |
| Endo USA, INC. | $69.75 | 2024-2025 | Aveed, Xiaflex |
| Tolmar, INC. | $62.05 | 2024-2025 | Eligard |
| Progenics Pharmaceuticals, INC. | $49.39 | 2025 | |
| Verity Pharmaceuticals INC. | $45.79 | 2025 | Trelstar |
| Bayer Healthcare Pharmaceuticals INC. | $36.57 | 2021-2023 | |
| Janssen Biotech, INC. | $34.66 | 2025 | Erleada |
| Urogen Pharma, INC. | $34.47 | 2023-2025 | Jelmyto |
| Endo Pharmaceuticals INC. | $29.86 | 2019-2020 | |
| Amgen INC. | $28.79 | 2020 | |
| Bioprotect Medical, INC. | $24.43 | 2025 | Bioprotect Balloon Implant System |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abc Home Medical Supply, INC. | $23.30 | 2025 | |
| Genzyme Corporation | $17.49 | 2021 | |
| Myriad Genetic Laboratories, INC. | $15.67 | 2021 | |
| Mindray Ds USA, INC. | $15.41 | 2022 | |
| Ferring Pharmaceuticals INC. | $15.05 | 2025 | Adstiladrin |
| Dentsply Ih INC. | $14.89 | 2021 | |
| Astellas Pharma US INC | $14.60 | 2021 | |
| Sumitomo Pharma America, INC. | $14.54 | 2024 | Gemtesa |
| Dendreon Pharmaceuticals LLC | $14.34 | 2019 | |
| Urovant Sciences INC | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alon Mass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.